The objective of this study was to investigate the prevalence of depression, anxiety, and insomnia among hospital staff working in a tertiary care private hospital in India during the early period of the COVID-19 pandemic.
Insomnia is often comorbid with psychiatric, medical, and neurologic disorders. Follow along as Dr Rosenberg discusses the bidirectional relationship between insomnia disorder and frequently co-occurring conditions.
Yawning is an unusual side effect of antidepressant medications. Here, read the case of a patient who developed yawning with every antidepressant she was prescribed, resulting in discontinuation of the medication.
In this brief report, the authors evaluate the effects of a possible association between different bupropion formulations and treatment-emergent insomnia in veterans with major depressive disorder prescribed bupropion based on provider discretion.
Evidence has shown that bipolar disorder is often linked to alterations in circadian rhythms. This study looked at the impact of these rhythms on suicide risk, as well as the role of hopelessness, in patients with bipolar disorder.
This study examined characteristics of pediatric psychiatric inpatients who experienced seclusion and restraint events and assessed if sleep time before and after the event was different from average sleep time during hospitalization.
Insomnia and short sleep duration are linked to increased morbidity from cardiometabolic and neuropsychiatric disorders. This study investigated the prevalence and common clinical correlates of insomnia with subjective short sleep duration.
Individuals with narcolepsy may experience not only academic, social, and occupational consequences but also dangerous driving or other accidents, meaning that effective treatment is critical. Here, review the evidence on treatment strategies.
Aside from intramuscular injection, few rapidly acting pharmacotherapeutic treatments are available for acute agitation. This study examined the safety and tolerability of INP105, a drug-device combination product that allows nasal delivery of olanzapine.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”